Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A. Salazar R, et al. Among authors: callies s. Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18. Cancer Chemother Pharmacol. 2014. PMID: 24744161 Clinical Trial.
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Koolen SL, et al. Among authors: callies s. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. doi: 10.1158/1078-0432.CCR-11-0353. Epub 2011 Jul 13. Clin Cancer Res. 2011. PMID: 21753156 Clinical Trial.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E. Faivre SJ, et al. Among authors: callies s. Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16. Invest New Drugs. 2015. PMID: 26377590 Clinical Trial.
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. Hong DS, et al. Among authors: callies s. Clin Cancer Res. 2011 Oct 15;17(20):6582-91. doi: 10.1158/1078-0432.CCR-11-0430. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831956 Free PMC article. Clinical Trial.
33 results